Bottneuro
Precision Medicine for Brain Health
- Headquarters
- Basel
- Employees
- 1–10
- Business Model
- B2B
- Website
- bottneuro.ch
- Last Round
- BridgeDec 2022
- Rounds
- 1
About
Bottneuro is a commercial-stage spin-off from the Department of Biomedical Engineering at the University of Basel. The company develops and markets Miamind, a neurostimulator that delivers personalized, non-invasive, home-based transcranial electrical stimulation (tES) for people with cognitive disorders. Bottneuro aims to improve lives affected by neurodegenerative and other cognitive conditions by pairing MRI-based personalization with at-home therapy that treating physicians can configure using simulated electrical-field parameters. Its operational team and clinical advisors focus on digital therapy for neurodegenerative disease, positioning Miamind as a precision-medicine approach to brain health.
Summary
Bottneuro is a Biotech company based in Basel, Switzerland. Its most recent funding was a Bridge round in Dec 2022.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Dec 2022
Similar Companies
Neuralink develops investigational implantable brain-computer interfaces that help people with pa...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/bottneuro"><img src="https://indexed.vc/api/badge/company/bottneuro" alt="Bottneuro on Indexed.vc" width="260" height="76" /></a>